Dual GIP/GLP-1 receptor agonists Sometimes called dual agonists or twincretins, as they activate the GLP-1 receptor plus a second receptor, called GIP (glucose-dependent insulinotropic polypeptide)
Simply complete our quick online medical assessment, and a UK-registered prescriber will review your details to approve your treatment
In January 2025, the FDA approved Ozempic (semaglutide) for kidney protection following the FLOW clinical trial, which demonstrated a 24% reduction in major kidney disease events
Nature 179 , 633634 (1957)
The problem is not that semaglutide dosing is complicated
PBMs can also be primary actors when they own pharmacies (typically either mail-order or specialty pharmacies), though this is a relatively recent development